CD8A and neoplasm: ScRNA- and TCR-seq of T cells, pre- and post-treatment, allowed the direct identification of a subset of tumor-infiltrating CD8+ T cells, clonally expanded during immunotherapy, with elevated tumor tissue-resident memory and cytotoxicity programs, deemed as the predominant T-cell population responding to neoadjuvant ICIs.